TTrialPathMatch Me to Trials
← Back to trials
RecruitingThyroid Eye DiseaseGraves OrbitopathyEndocrine System Diseases

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Eligible age

18+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.

Sponsor: Sling Therapeutics, Inc.

You may qualify if…

  • ✓ Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (\< 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301
  • ✓ Subject has not received any treatment for TED since Week 24 of VGN-TED-301
  • ✓ Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \[FT4\] and free triiodothyronine levels \[FT3\] \<50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial
  • ✓ Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study

You may not qualify if…

  • ✕ The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.

Where it's recruiting

Florida

Miami

West Virginia

Morgantown

Source: ClinicalTrials.gov · NCT06112340 · last updated 2025-02-25